Regulatory aspects for Biologic Product licensing in Australia
Journal Title: International Journal of Drug Regulatory Affairs - Year 2019, Vol 7, Issue 2
Abstract
The TG Act defines biological as product made, from or containing, human cells or human tissues, lives animal organs, cells or tissues, and that is used to treat or prevent disease or injury, Diagnose a condition of a person and Alter the physiological processes of a person. The Australian Regulatory Guidelines for Biologicals (ARGB) provide the keen information for manufacturers, sponsors, professionals in healthcare and also to public about the use of human cells and tissues based therapeutic goods, live animal cells, organs and tissues (1). These all products are Biologicals. This guideline is specially written for general public. If you are a sponsor or manufacture, this will: • Explains the biological regulatory framework is applies to manufacturer’s product and their exemption conditions (1). • Explains the Australian regulatory requirements for supplying of Biologicals • Explains what is required for the market authorization as per TGA especially for Biologicals.
Authors and Affiliations
Sanjeev Kumar Maurya, Vikesh Kumar Shukla, Sunny Kumar Maurya, Prachi Kaushik, Indu Maurya
Keywords
Related Articles
- EP ID EP625605
- DOI 10.22270/ijdra.v7i2.310
- Views 107
- Downloads 0
MARKETING AUTHORIZATION APPLICATION (MAA) FOR EUROPE MARKET
This article states requirement of Marketing Authorization Application to get registration of Drug Product to EEA. The procedures for application of marketing authorization are: Centralised procedure, National procedure,...
REGULATORY TECHNICALITIES FOR DRUG PRODUCT REGISTRATION IN BRAZIL
Brazilians are demanding better healthcare and modern medicines, presenting significant opportunities for foreign investment. In Brazil, medicinal product registration is an extensive process. To do business in Brazil is...
Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review
In the healthcare industry, the biggest challenges are cancer. However, there are several drugs are available for the treatment of cancer. In these treatments cure cancer affecting the collateral toxicity to healthy cell...
Regulatory requirements for Drug master file in context to Canada and Australia
Drug Master Files are required in most countries as supporting documents for the registration of drug products. DMFs generally contain information pertaining to the chemistry, manufacturing and controls (CMC) sections of...
METHOD DEVELOPMENT AND VALIDATION OF STABILITY INDICATING UPLC ASSAY METHOD FOR NIFEDIPINE
A simple and rapid stability indicating, ultra performance liquid chromatographic (UPLC) method was developed and validated for the determination of Nifedipine. The quantitative determination of Nifedipine drug was perfo...